MRTX News and Press, Mirati Therapeutics Inc. From 09/15/22

Piper Sandler launched its coverage on oncology-focused biotech Mirati Therapeutics, Inc. ( NASDAQ: MRTX ) with an Overweight rating and a $110 per share target on Thursday, citing the potential of its experimental cancer therapy adagrasib compared to a rival drug from Amgen ( ...

Summary Today, we circle back on a small oncology outfit called Verastem, Inc. The company is steadily advancing its pipeline targeting both LGSOC and NSCLC and Verastem secured funding this year to carry out its multiple trials. An investment analysis follows in the paragraph...

Good news from the Food and Drug Administration (FDA) can send biotech stocks into the stratosphere. And bad news can bring their share prices crashing down. Our Foolish trio is optimistic about Mirati Therapeutics (NASDAQ: MRTX) , Novavax (NASDAQ: NVAX) and Heron Therapeu...

Summary Mirati has strong competitive differences against larger rival Amgen. However, lead indication, 2nd line NSCLC, is not where these differences will come out. Investors need to be patient and wait for combo data, 1st line NSCLC and especially CRC for Mirati to really st...

Mirati Therapeutics Presents Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer PR Newswire Adagrasib demonstrates promising clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavil...

The shares of clinical-stage biotech Mirati Therapeutics ( NASDAQ: MRTX ) added ~11% in the pre-market trading Wednesday after Amgen ( AMGN ) announced a lung cancer medication that rivals the company’s key asset adagrasib reached the primary objective in a la...

KRAS is important in the signaling cascade in some big cellular proliferation and growth pathways, which are inappropriately set pedal-to-the-metal in these tumor types. Amgen has now reported results of a trial of their drug as a combination therapy with two of the big immuno-oncolog...

Mirati Therapeutics ( NASDAQ: MRTX ) added ~10% in the pre-market Monday after Amgen ( AMGN ) posted Phase 1 data for the rival KRAS inhibitor Lumakras, highlighting liver side effects of the cancer drug in combination with immunotherapies. In 2021, Lumakras became...

Mirati Therapeutics, Inc. (MRTX) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - Chief Executive Officer Chuck Baum - President, Founder & Head of Research & De...

Mirati Therapeutics press release ( NASDAQ: MRTX ): Q2 GAAP EPS of -$3.18 beats by $0.32 . Revenue of $5.36M beats by $4.98M . For further details see: Mirati Therapeutics GAAP EPS of -$3.18 beats by $0.32, revenue of $5.36M beats by $4.98M